192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study. (December 2022) - Di Giacomo, A.M.; Santangelo, F.; Amato, G.; E. Simonetti,; Graham, J.; Lahn, M.; van der Veen, L.; Hammett, T.; Pickering, C.A.; Durini, M.; Ziyang, T.; Lakshmikanth, T.; et al.